SEC For	rm 4 FORM	4 L	JNITE	) STA	TES	SE	CUR	2 <b> T </b>	ES AND	) E	ХСНА	NG	E C	OMN	IISSION	I				
		Washington, D.C. 20549											OME	APPRO	VAL					
Section 16. Form 4 or Form 5 obligations may continue. See						T OF CHANGES IN BENEFICIAL OWNI d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										COMB Num Estimated hours per			3235-0287 en 0.5	
1. Name and Address of Reporting Person <sup>*</sup> CHASE WILLIAM J						2. Issuer Name <b>and</b> Ticker or Trading Symbol Intellia Therapeutics, Inc. [NTLA]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last)						3. Date of Earliest Transaction (Month/Day/Year) 06/14/2023									Officer (give title Other (specify below) below)					
C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET, SUITE 130 (Street)					4. lf /	Line) X Form										Joint/Group Filing (Check Applicable filed by One Reporting Person filed by More than One Reporting				
CAMBRIDGE MA 02139						Rule 10b5-1(c) Transaction Indication														
(City)															led to					
		Tabl	e I - Nor	n-Deriv	ative	Sec	uritie	s Ac	cquired, C	Disp	osed (	of, or	r Ben	eficia	lly Owne	d				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da						) E>	2A. Deemed Execution Date if any (Month/Day/Yea		Code (Inst						5. Amount of Securities Beneficially Owned Followir Reported		Forr (D) o	wnership n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	t (	(A) or (D)	Price	Transac	ansaction(s) astr. 3 and 4)			(instr. 4)	
Common Stock <sup>(1)</sup> 06/14/2					/2023	023		А		1,67	73 A S		\$ <mark>0.0</mark>	00 18,956			D			
		Та							juired, Dis s, options			'			y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,	4. Transactio Code (Ins 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	s Ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownershi (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		piration	Title		Amount or Number of Shares						
Stock Option (right to buy)	\$45.2	06/14/2023			A		2,447		(2)	06	/13/2033	Comn Stoc		2,447	\$0.00	2,447		D		

Explanation of Responses:

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

2. This option was granted on June 14, 2023 with respect to 2,447 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.

**Remarks:** 

<u>/s/James Basta, Attorney-In-</u> <u>Fact</u>

06/16/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.